{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:12:51Z","timestamp":1793041971370,"version":"4.5.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>During present decade, targeted drug therapy has been the epitome for treatment of cancer. Drugs like Imatinib, a tyrosine kinase receptor inhibitor and Trastuzumab, an human epidermal growth factor receptor-2\/neu inhibitor, has been developed and accepted widely for management of chronic myeloid leukaemia and breast cancer respectively. Recent development among the various immunotherapies is adoptive cell transfer (ACT). Research on development of various types of ACT immunotherapy is going on, but so far, Chimeric antigen receptors T cell therapy (CAR-T) has achieved the maximum advancement in terms of clinical development. CARs are the modified receptors that integrates specificity and responsiveness onto immune cells to enhance the recognition of cancer cells. For the CAR-T, the T cells are sequestered from a blood of a participant via apheresis. DNA of particular antigen is injected into harvested T cells to generate CARs on cell surface. Following surface manifestation of receptors, multiplication is carried out in enriched media followed by infusion into patient. After infusion, CAR-T cells targeted and exterminate the cancer cells. Initially, only two drugs targeting CD19 as genetically modified autologous immunotherapy has been approved in CAR-T therapy i.e., Tisagenlecleucel and Axicabtagene Ciloleucel, which are discussed in detail in current review. Recently two more drugs got approval i.e., brexucabtagene ciloleucel and lisocabtagene maraleucel, both are directed against CD19, similar to tisagenlecleucel. CAR-T cell therapy is approved for management of Acute Lymphoblastic Leukaemia, Chronic Lymphocytic Leukaemia and lymphoma. CAR-T cell persistence responsible for effectiveness and safety concerns are barriers for their wide application among patients. Growth factor receptors and cluster of differentiation are new drugs targets that are being explored as effective immunotherapy against cancers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijp.ijp_531_20","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T15:51:03Z","timestamp":1716479463000},"page":"226-233","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":23,"title":["Chimeric antigen receptor T cell"],"prefix":"10.4103","volume":"54","author":[{"given":"Surjit","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Khasbage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimple Jeet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaspreet Kaur","family":"Sidhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharti","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-11-20240903","first-page":"189","article-title":"Statistical analysis of accomodative convergence (AC-A ratio)","volume":"83","author":"Franceschetti","year":"1970","journal-title":"Bull Mem Soc Fr Ophtalmol"},{"key":"R3-11-20240903","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","article-title":"Engineering CAR-T cells","volume":"5","author":"Zhang","year":"2017","journal-title":"Biomark Res"},{"key":"R4-11-20240903","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"TRUCKs: The fourth generation of CARs","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"R5-11-20240903","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.humimm.2018.09.007","article-title":"CRISPR\/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment","volume":"79","author":"Mollanoori","year":"2018","journal-title":"Hum Immunol"},{"key":"R6-11-20240903","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1002\/eji.201545552","article-title":"Adoptive T-cell therapy for cancer: The era of engineered T cells","volume":"45","author":"Bonini","year":"2015","journal-title":"Eur J Immunol"},{"key":"R7-11-20240903","doi-asserted-by":"crossref","first-page":"e985924","DOI":"10.4161\/2162402X.2014.985924","article-title":"MHC-I modulation due to changes in tumor cell metabolism regulates tumor sensitivity to CTL and NK cells","volume":"4","author":"Catal\u00e1n","year":"2015","journal-title":"Oncoimmunology"},{"key":"R8-11-20240903","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.blre.2015.10.003","article-title":"Chimeric antigen receptor T cell therapy: 25 years in the making","volume":"30","author":"Gill","year":"2016","journal-title":"Blood Rev"},{"key":"R9-11-20240903","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2174\/1574888X13666180420110239","article-title":"Chimeric antigen receptor T cell based immunotherapy for cancer","volume":"13","author":"Li","year":"2018","journal-title":"Curr Stem Cell Res Ther"},{"key":"R10-11-20240903","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/2040620714550773","article-title":"Role of allogeneic transplantation in patients with chronic lymphocytic leukemia in the era of novel therapies: A review","volume":"5","author":"Mewawalla","year":"2014","journal-title":"Ther Adv Hematol"},{"key":"R11-11-20240903","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"key":"R12-11-20240903","doi-asserted-by":"crossref","first-page":"10748","DOI":"10.18632\/oncotarget.13314","article-title":"Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"R13-11-20240903","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/S0140-6736(96)90871-5","article-title":"Graft-versus-myeloma effect in two cases","volume":"347","author":"Verdonck","year":"1996","journal-title":"Lancet"},{"key":"R14-11-20240903","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1146\/annurev-med-051914-021702","article-title":"CAR-T cell therapy for lymphoma","volume":"67","author":"Ramos","year":"2016","journal-title":"Annu Rev Med"},{"key":"R17-11-20240903","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"R18-11-20240903","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"key":"R19-11-20240903","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"R20-11-20240903","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.19.01892","article-title":"Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J Clin Oncol"},{"key":"R21-11-20240903","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","article-title":"Managing cytokine release syndrome associated with novel T cell-engaging therapies","volume":"20","author":"Maude","year":"2014","journal-title":"Cancer J"},{"key":"R22-11-20240903","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/sji.12331","article-title":"CD19-chimeric antigen receptor T cells for treatment of chronic lymphocytic leukaemia and acute lymphoblastic leukaemia","volume":"82","author":"Lorentzen","year":"2015","journal-title":"Scand J Immunol"},{"key":"R23-11-20240903","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"R24-11-20240903","doi-asserted-by":"crossref","first-page":"107419","DOI":"10.1016\/j.pharmthera.2019.107419","article-title":"Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions","volume":"205","author":"Bagley","year":"2020","journal-title":"Pharmacol Ther"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_531_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:45:51Z","timestamp":1787769951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_531_20"}},"subtitle":["A cancer immunotherapy"],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_531_20","relation":{},"ISSN":["0253-7613"],"issn-type":[{"value":"0253-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}